Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5205480
Max Phase: Preclinical
Molecular Formula: C24H26ClN5O6
Molecular Weight: 515.95
Associated Items:
ID: ALA5205480
Max Phase: Preclinical
Molecular Formula: C24H26ClN5O6
Molecular Weight: 515.95
Associated Items:
Canonical SMILES: C=CC(=O)Nc1cc(Nc2ncc(Cl)c(O[C@@H]3CO[C@H]4[C@@H]3OC[C@H]4O)n2)ccc1N1C[C@@H]2C[C@H]1CO2
Standard InChI: InChI=1S/C24H26ClN5O6/c1-2-20(32)28-16-5-12(3-4-17(16)30-8-14-6-13(30)9-33-14)27-24-26-7-15(25)23(29-24)36-19-11-35-21-18(31)10-34-22(19)21/h2-5,7,13-14,18-19,21-22,31H,1,6,8-11H2,(H,28,32)(H,26,27,29)/t13-,14-,18+,19+,21+,22+/m0/s1
Standard InChI Key: MXJZKDHDEKITDX-WRRICFGBSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 515.95 | Molecular Weight (Monoisotopic): 515.1572 | AlogP: 1.88 | #Rotatable Bonds: 7 |
Polar Surface Area: 127.30 | Molecular Species: NEUTRAL | HBA: 10 | HBD: 3 |
#RO5 Violations: 1 | HBA (Lipinski): 11 | HBD (Lipinski): 3 | #RO5 Violations (Lipinski): 2 |
CX Acidic pKa: 13.21 | CX Basic pKa: 2.32 | CX LogP: 2.21 | CX LogD: 2.21 |
Aromatic Rings: 2 | Heavy Atoms: 36 | QED Weighted: 0.47 | Np Likeness Score: -0.27 |
1. Li S, Si H, Song X, Lei C, He X, Wang J, Liu Y, Zhou Y, Song JG, Peng L, Tang X, Chan S, Ren X, Tu Z, Li Z, Wang Z, Zhang Z, Ding K.. (2022) Discovery of Hexahydrofuro[3,2-b]furans as New Kinase-Selective and Orally Bioavailable JAK3 Inhibitors for the Treatment of Leukemia Harboring a JAK3 Activating Mutant., 65 (15.0): [PMID:35860875] [10.1021/acs.jmedchem.2c00922] |
Source(1):